Elevance Health reports 15% revenue growth in Q1 2025 driven by Medicare Advantage expansion, premium increases, and CarelonRx portfolio growth, highlighting ongoing healthcare market evolution.

President Trump's executive order prompts potential changes in Medicare drug price negotiation, affecting pharmaceutical pricing, Medicare spending, and FDA drug import regulations. Epic Systems also shifts to a more public presence in healthcare IT.

Analysis of Medicare affordability challenges highlights systemic issues and the need for reform in traditional Medicare and Medicare Advantage plans affecting coverage and costs.

CMS finalizes critical 2026 Medicare Advantage rule changes, including anti-obesity drug coverage exclusion, AI regulatory deferral, and limits on retroactive inpatient stay denials affecting payers and providers.

Elevance Health reports steady Q1 profits with growth in Medicare Advantage and Carelon despite elevated medical costs and legal challenges.

Elevance Health's Q1 report shows Medicare Advantage utilization in line with expectations, Medicaid rate progress, and ACA expansion amid market volatility.

Mark Farrah Associates reports a slowdown in Medicare Advantage market growth with detailed enrollment and market share data for early 2025. Key tools aid insurers in competitive analysis post-Open Enrollment Period.

April 2025 market update reveals insurer stock declines amid UnitedHealth earnings miss, offset by pharma gains led by Eli Lilly's drug innovation and strong healthcare sector earnings projections.

Medicare Advantage increases federal spending but offers lower out-of-pocket costs for seniors. SCAN CEO Sachin Jain highlights program flaws, risk adjustment abuses, and broker roles.

UnitedHealth Group reports a return to profitability in Q1 2025 with $6.4B net earnings, revises 2025 earnings outlook amid Medicare Advantage and Optum challenges.